Targeting CD30 helps dual-specificity CAR T cells improve themselves
August 21, 2019
In the hunt to expand the arsenal of checkpoint regulators, Hombach et al. investigated the possibility of targeting the CD30-CD30L axis. CD30 and/or CD30L can be expressed on a number of immune cells (T cells, B cells, and some APCs), and prior evidence has suggested that it may play a role in limiting...
The interferon seesaw between tumor cells and immune cells determines response to immune checkpoint blockade
August 14, 2019
Interferon is full of paradoxes. Some patients have cancers with a mutated IFN pathway, but still respond to immune checkpoint blockade (ICB). Other patients have high serum levels of IFNγ, but their cancer progresses with ICB treatment. IFNγ can boost immune function, but also promotes T cell exhaustion via upregulation of PD-L1. In...
The timing of priming and PD-1 blockade
August 7, 2019
Checkpoint blockade of the PD-1 axis (PD-1 or PD-L1) can be effective in inducing antitumor immunity, although many patients still relapse or fail to derive clinical benefit at all. Combinations of anti-PD-1 treatment with vaccines against tumor-associated antigens or with other immunomodulatory agents are actively being explored, and optimal timing and sequencing have...